FAQ’s
Find out more about our accelerator programmes, the application process and how you can get involved below
We are now accepting applications for our Diagnostics Accelerator Programme with London Invitro Diagnostics Co-operative, find out more
Making multiple applications will not negatively impact the assessment of your application.
We always welcome new partnerships and collaborators. Please email us at mtsc@imperial.ac.uk for a more detailed discussion.
All of our accelerator programmes that offer a salary replacement for early career researchers released onto the programme are considered a fulltime commitment. The Venture Accelerator is an eight programme and the Challenge Accelerator is a six month programme.
PhD students are eligible subject to the following conditions – your supervisor would be happy for you to interrupt your PhD, interrupting your PhD will not negatively impact on your PhD, your PhD is not funded in a way that would be jeopardised if you were to interrupt your PhD.
The principal investigator will not necessarily be the existing PhD supervisor.
MedTech SuperConnector does not take IP. The IP ownership will reside within the respective HEI(s) associated with the participant(s).
The main purpose of the funding is to enable teams to work on their projects directly. Any external advice or consultancy should be kept to a minimum.
We will be opening applications for the Diagnostics Accelerator Programme in early February 2021.
The deadline for applications is 11:59 GMT Sunday 7 March 2021
Panel interviews are scheduled for the week of the 22nd March 2021
There is a possibility that we can arrange for an alternative date, but we cannot guarantee that there will still be places available on the cohort following the scheduled interview dates.
The online programme orientation day is important part of your induction to the progamme covering expectations and learning outcomes.
The value in this programme sits with the opportunity to collaborate directly with the London In Vitro Diagnostics to develop a business case that de-risks and validates all of your clinical, financial and social claims with appropriate evidence from a respected body. This way, when you approach the health system, they are comfortable in the knowledge that your product achieves what it is designed to do. Unlike our six and eight month accelerators this programme does not include a salary replacement scheme or project funding.
Participating in this programme will not change or affect the status of any IP.
Remaining agile and responsive to the changing circumstances is our number one priority and we aim to continue to deliver all aspects of the programme to the same high standard. We are monitoring the situation closely and will be carrying out all recruitment activity digitally along with the learning the portion of the programme for the foreseeable future.
Become a member
Join our mailing list to receive updates about Medtech SuperConnector.
You can unsubscribe by clicking the link in our emails where indicated, or emailing mtsc@imperial.ac.uk. Or you can update your contact preferences. We promise to keep your details safe and secure. We won’t share your details outside of Medtech Superconector without your permission. Find out more about how we use personal information in our Privacy Policy.